

MINUTES OF THE ACADEMIC AND STUDENT AFFAIRS COMMITTEE
UNIVERSITY OF LOUISVILLE BOARD OF TRUSTEES

In Open Session

The Academic and Student Affairs Committee of the University of Louisville Board of Trustees met on Thursday, October 6, 2005, in the Conference Room of Med Center Three, with members present and absent as follows:

Present: Prof. William Pierce, Chairman
Mr. William Brammell, Jr., Vice Chair
Dr. Salem George
Mr. Bill Forman
Dr. Robert Curtis Hughes

Absent: Mr. Tommie Burns
Ms. Jessica Loving

Other Trustees

Present: Ms. Marie Abrams
Mr. Ulysses L. Bridgeman, Jr.
Mr. Kevin Cogan
Mr. Nathaniel E. Green
Mr. Steve Poe
Ms. Sandy Metts Snowden
Mr. Bill Stone
Ms. Elizabeth Worland

From the
University:

Dr. James R. Ramsey, President
Dr. Shirley Willihnganz, Executive Vice President and Provost
Ms. Angela D. Koshewa, University Counsel
Dr. Larry Cook, Executive Vice President & Chancellor for HSC
Mr. Larry Owsley, Vice President for Business Affairs
Dr. Nancy C. Martin, Senior Vice President for Research
Mr. Ronald L. Moore, Vice President for Information & Technology
Mr. Jim Zanewicz, Technology Transfer, VP Research Office
Mr. John Drees, Interim Associate VP for University Advancement
Mrs. Kathleen M. Smith, Assistant Secretary
Ms. Debbie Dougherty, Board Liaison

Guests: Dr. Steve Gailar, Metacyte
Dr. Benjamin Mast, Arts & Sciences

I. Call to Order

Having determined a quorum present, Chair Pierce called the meeting to order at 3:30 p.m.

Approval of Minutes, July 14, 2005

Mr. Brammell made a motion, which Mr. Forman seconded, to approve the minutes of July 14, 2005. The motion passed unanimously.

II. Information Items: Presentations from

Steve Gailar and James Zanewicz

President Ramsey introduced Dr. Steve Gailar and Mr. James Zanewicz. Dr. Gailar is president of Metacyte and Mr. Zanewicz heads the Office of Technology Transfer (OTT) for the University of Louisville. Mr. Zanewicz reported OTT's mission encompasses discovery, innovation and the transfer of information to the public sector. UofL strives to disseminate the knowledge developed by faculty, staff, other employees and students and protects the interests of the Commonwealth through a recovery by the University from its investment in research. MetaCyte Business Lab LLC is the venture development subsidiary of Louisville Medical Center Development Corporation (LMCDC). Metacyte Business Lab was incorporated by Jewish Hospital HealthCare Services, Inc., Norton HealthCare, Inc., UofL Health Care and the University of Louisville. Metacyte Business Lab identifies promising life science research and healthcare technology by prospecting within state universities, health care institutions, industry and the community. It then drives the life science research to market and clinic, by creating and assisting in the development of high-growth start-up companies. Dr. Gailar briefly explained the start-up company licensure requirements. LMCDC's vision was to make the Louisville Medical Center the next significant health science commercialization center in the United States. Mr. Zanewicz explained Metacyte was a start-up manufacturing company with raw intellectual capital from technology, clinicians and investigators that creates products through life science and healthcare technology companies. Metacyte companies include RhinyCyte, PGx, EndoProtech, Asotabio, InnoRem. Dr. William Pierce discussed Pradama, which is a specialty pharmaceutical company focused on the development and commercialization of products to treat bone disorders – metabolic disease and fracture. Pradama has a lead product for the prevention and/or treatment of osteoporosis. Dr. Pierce introduced the management team of Pradama and reported that Pradama acquired in May 2005 the exclusive worldwide rights to the following intellectual property from the UofL Research Foundation: 1) Compounds for Diagnosis, Treatment and Prevention of Bone Injury and Metabolic Disorders; and 2) Bone Targeting Compounds for Delivering Agents to the Bone for Interaction Therewith. He noted the estimated revenues of drugs to treat osteoporosis were \$8.2 billion in 2003, and were projected to reach \$14.4 billion in 2008. Dr. Pierce said existing drugs for osteoporosis fall under two categories: anti-resorptive agents that work to slow bone breakdown, and anabolic agents that stimulate new bone formation. Pharmacotherapy for bone diseases—especially osteoporosis—is a competitive market. Dr. Pierce explained that Pradama has received approximately \$800,000 in support of basic research to date. KSTC provided a grant supporting work with the UK College of Pharmacy. Pradama will need approx. \$1.9 million to reach threshold. Dr. Pierce thanked Board members for their support.

Benjamin Mast

President Ramsey introduced Dr. Benjamin Mast, Assistant Professor in the Department of Psychological and Brain Sciences of the College of Arts & Sciences. Dr. Mast completed his undergraduate in psychology at Calvin College and his Ph.D. in Clinical Psychology at Wayne State University. Prior to joining the faculty at UofL, he completed a doctoral internship in the School of Medicine at the University of Washington in Seattle. During doctoral training, Dr. Mast's research received a number of awards including the American Geriatrics Society New Investigator Award for 2005. He thanked the trustees for inviting him to the meeting. Dr. Mast described his research as the intersection of [clinical geropsychology](#), rehabilitation psychology, and neuropsychological assessment. More specifically his research focuses upon (1) methodological innovation in clinical research (i.e., application of structural equation model techniques to clinical questions), (2) assessment and detection of late life syndromes (e.g., vascular dementia, Alzheimer's disease), (3) examination of specific hypotheses concerning the prevalence, expression, and clinical correlates of late life cognitive and mood disorders including post-stroke depression and vascular depression, and (4) development of interventions tailored to match the needs of the specific sub-groups within the geriatric patient population. Chair Pierce thanked Dr. Mast for an excellent presentation, and the Board recognized Dr. Mast's achievement with a round of applause.

III. Adjournment

Mr. Brammell made a motion, which Dr. George seconded, to adjourn the meeting. The motion passed unanimously.